OPNT: Opiant Pharmaceuticals, Inc. - Summary | Jitta

Opiant Pharmaceuticals, Inc.

NASDAQ:OPNT

Notice
Stock data is unavailable or the company’s delisted.
Price
$20.65
Loss Chance
58.0%
1.95JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (22)
Recent Business Performance (9)
Financial Strength (51)
Return to Shareholders (18)
Competitive Advantage (32)
Jitta Signs
Debt LevelLow Long Term Debt
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2018
Operating MarginInconsistent
Recent Business PerformanceEarning decline 305.35% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
Key Stats
Jitta Score
Jitta Line
1.95
100.00%
3.03
208.13%
3.05
162.56%
Pharmaceuticals
5.41
69.27%
2.33
16.57%
5.69
90.01%
COMPANY DESCRIPTION
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California. As of March 2, 2023, Opiant Pharmaceuticals, Inc. operates as a subsidiary of Indivior PLC.